How to Check Goldline Pharmaceutical IPO Allotment Status

Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name "Goldline." Its product range is divided into five segments: Goldline Pharma (42 products catering to Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology), Goldline Cardinal (54 products for Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians), Goldline Aayushman (18 products for Pediatricians, Child Specialists, Neonatologists, and General Practitioners), Goldline InLife (22 products for Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians), and Goldline Wellness (10 products for supportive care in cancer therapy).

The company does not manufacture products, but partners with third-party manufacturers who produce medicines based on its market research and product specifications, ensuring quality and compliance with regulations. It currently works with 15 manufacturers and 7 distributors, and sells products across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

Goldline Pharmaceutical IPO is a book build issue of ₹11.61 crore, entirely comprising a fresh issue of 0.27 crore shares aggregating to ₹11.61 crore. The IPO opened on May 12, 2026, and closed on May 14, 2026. The allotment is expected on Friday, May 15, 2026. The share price band was set at ₹41 to ₹43 per share.
 

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Goldline Pharmaceutical IPO Allotment Status on Registrar Site

• Visit the Bigshare Services Pvt. Ltd.
• Select "Goldline Pharmaceutical" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Goldline Pharmaceutical IPO Allotment Status on BSE

• Navigate to the BSE SME IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Goldline Pharmaceutical" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Goldline Pharmaceutical IPO subscribed 840.50 times overall. Here is the category-wise breakdown as of 4:59:34 PM on May 14, 2026:

Goldline Pharmaceutical IPO Subscription Status

• QIB Category (Ex Anchor): 180.22 times
• Non-Institutional Investors (NII): 1,661.99 times
• Individual Investors: 880.68 times

Goldline Pharmaceutical IPO Share Price and Investment Details

The minimum investment required was ₹2,58,000 for 2 lots (6,000 shares) for individual investors. The issue raised ₹3.15 crore from anchor investors. The issue includes a reservation of up to 1,38,000 shares for the market maker, Nirman Share Brokers Pvt. Ltd. The anchor investor lock-in period ends on June 14, 2026 for 50% of shares (30 days) and August 13, 2026 for the remaining shares (90 days). Given the overall subscription of 840.50 times with strong institutional interest at 180.22 times, exceptional NII participation at 1,661.99 times, and robust individual investor subscription at 880.68 times, the share price listing expectations remain highly positive.

Utilisation of IPO Proceeds

The proceeds will be utilised for prepayment or repayment of all or a portion of certain outstanding borrowings availed by the Company (₹8.35 crore) and general corporate purposes.

Business Overview

Goldline Pharmaceutical Limited is engaged in the business of marketing pharma products under the "Goldline" brand. It is fully dependent on third-party supplies, which raises a major concern. Higher margins posted by it compared to listed peers also raise eyebrows.

The company demonstrated financial performance with total income of ₹28.06 crore for FY2025 and a net worth of ₹12.36 crore as of December 31, 2025. The company benefits from experienced promoters and management team with industry knowledge and a track record, an asset-light business model with competitive products, a scalable business model, a wide and diverse range of product offerings, strong supplier and vendor relationships, and an established distribution network. However, investors should note the post-issue P/E ratio of 13.93 and Price to Book Value of 3.47.